

**KCNQ Channels and Novel Insights Into Coronary Perfusion**

Maik Gollasch

---

**K**v7 (KCNQ) voltage-gated potassium channels are encoded by the KCNQ gene family, many of which display highly restricted and distinct tissue distribution. Cloning experiments have identified 5 KCNQ genes (KCNQ1–5). Mutations in 4 of the 5 genes of the KCNQ gene family have been associated with inherited diseases. KCNQ1 mutations cause cardiac arrhythmia in long QT syndrome with or without deafness. KCNQ2 and KCNQ3 mutations cause benign familial neonatal seizures and peripheral nerve hyperexcitability. Mutations in KCNQ4 underlie congenital deafness and modulate cutaneous touch sensitivity in man.1,2 No human disease has been related to KCNQ5 until now. KCNQ1, 3, 4, and 5 gene products are widely expressed in systemic arteries with KCNQ 4 and 5 being predominant.3–5 Current data suggest important roles for Kv7 family in systemic peripheral arteries, namely myogenic response and vasoregulation by vasopressin,β-adrenoceptors, hydrogen sulfide, and perivascular adipose tissue.5,9

In this current issue, Khanamiriet al have examined the possible role of Kv7 channels in the rat coronary circulation. They report expression of KCNQ and their known accessory KCNE1–5 subunits. Their study relied on pharmacological modulators of KCNQ channels in isometric tension studies of isolated coronary arteries and Langendorff-perfused hearts to explore a possible role of KCNQ channels in coronary blood flow at rest and in response to ischemia. Of interest was the observation that vasodilatory effects of a key mediator of coronary ischemic vasodilation, namely adenosine, are inhibited by Kv7 blockers. The results suggest that adenosine through adenosine A2 receptors and cAMP protein pathway activates Kv7 channels (Figure). This is the first time that this signaling pathway has been observed in vascular smooth muscle. Of note, vasorelaxant effects of Kv7.2 to 7.5 activators were absent in coronary arteries isolated from spontaneously hypertensive rats, consistent with lower expression of Kv7.4 protein, reduced vasodilatory effects of adenosine, and attenuated level of reactive hyperemia in hearts from spontaneously hypertensive rats. The authors conclude that Kv7 channels provide a crucial functional end point for adenosine-mediated signaling in coronary arteries. To my knowledge, this study is the first example of a faulty (or absent) KCNQ channel(s) (Kv7.4) as being responsible for coronary perfusion and restoration of cardiac reperfusion after transient coronary occlusion. The results suggest that Kv7.4 becomes dysfunctional in the coronary circulation in hypertension. This work supports a growing paradigm shift in the role of Kv7 channels in coronary circulation because 4-aminopyridine–sensitive Kv7 channels are considered to play the most central role in regulating coronary blood flow (Figure) and these channels are reported to be involved in resting vascular tone, as well as endothelium-dependent, ischemic, and metabolic coronary vasodilation.11

Admittedly, work with pharmacological tools is fraught with confounders. Pharmacological modulators of Kv7 channels may have side effects on non-KCNQ Kv channels. Khanamiriet al tried to rule out such possibilities using a large repertoire of structurally different Kv7 channel blockers and agonists. Experiments with 4-aminopyridine were performed to rule out nonspecific block of non-KCNQ Kv channels. Nonetheless, it was surprising that prolonged infusion with XE-991 or linopirdine (Kv7 blockers) to the isolated hearts only resulted in a very modest reduction of coronary flow. Based on previous data and current views,11 one would have expected a much more profound reduction in blood flow if KCNQ channels had the proposed prominent role in the

---

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Medical Clinic for Nephrology and Internal Intensive Care, Charité Campus Virchow Klinikum, Experimental and Clinical Research Center (ECRC), Berlin, Germany.

Correspondence to Maik Gollasch, Medical Clinic for Nephrology and Internal Intensive Care, Charité Campus Virchow Klinikum, Experimental and Clinical Research Center (ECRC), Augustenburger Platz 1, 13353 Berlin, Germany. E-mail maik.gollasch@charite.de

*Hypertension* 2013;62:1011-1012.

© 2013 American Heart Association, Inc.

*Hypertension* is available at [http://hyper.ahajournals.org](http://hyper.ahajournals.org)

DOI: 10.1161/HYPERTENSIONAHA.113.01869
regulation of coronary artery function (Figure). It is unclear whether 10 µmol/L linopirdine+3 µmol/L XE-991 are sufficient to inhibit a significant proportion of Kᵥ7.4 channels in coronary arteries. The role of the known accessory KCNE1–5 subunits is unclear. Recent data implicate that unsaturated heteromultimeric (KCNQ)₁₄(KCNE₁)ₙ channels are pharmacologically distinct from KCNE-saturated KCNQ₁–KCNE₁ channels.² The present study supports a central role of KCNQ channels in the regulation of coronary blood flow.¹² However, given issues with drug specificity and possible heteromultimeric channel complexes, it will be critical to incorporate appropriate genetic models to establish firmly the roles of KCNQ channels in vascular function. Thus, we could find out which Kᵥ/V₇/KCNE channels are involved.

**Sources of Funding**

Dr Gollasch’s research is supported by the Deutsche Forschungsgemeinschaft.

**Disclosures**

None.

**References**

KCNQ Channels and Novel Insights Into Coronary Perfusion
Maik Gollasch

Hypertension. 2013;62:1011-1012; originally published online September 30, 2013;
doi: 10.1161/HYPERTENSIONAHA.113.01869

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/62/6/1011

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/